Geron Corporation · NASDAQ:GERN
Geron — Investor Presentation (January 2016)
15 slides from Geron's investor presentation, Jan 11, 2016
Slide 1: January Corporate Presentation
January Corporate Pri John Scarlett, M.D.
Slide 2: Forward-Looking Statements
ooking Statements Except for the historical information contained herein, this presentation contains forward-looking statements made pursuant to the "safe harbor” provisions of the Private Securities Litigation Reform Act of 1985. Investors are cautioned that statements in tis press release regardin
Slide 3: Highlights
lighlights Continuing clinical data indicate broad and transformative potential of imetelstat + New England Journal of Medicine publications in September 2015 = Data from trials in essential thrombocythemia {ET) and myelofibrosis (MF) suggest disease-modifying activity + Presentations at American So
Slide 4: Clinical Data Suggest Transformative Potential of Imetelstat
Clinical Data Suggest rmative Potential of Imetelstat Proof-of-concept study in essential thrombocythemia + Compelling and durable hematologic and molecular responses + Molecular responses suggest effect on underlying malignant progenitor cell clones Pilot study in myelofibrosis + Unprecedented comp
Slide 5: Janssen Collaboration Structure and Economics
First Stage Continuation Stage IMerge™ (Phase 2/3 MDS study) + Janssen conducting IMbark™ and IMerge"™* + Janssen to provide Continuation Decision following primary analysis of IMbark™ First Stage Economics Upfront Cost share 335M 50% Geron 50% Janssen Phase 3: MF, MDS Phase 2: Ad Phase 2,3: AML tio
Slide 6: Myelofibrosis (MF)
‘osis (MF) racteristics malignant : hematopoietic moar ey a zat Qe cookings mane yells retain fibers precursors fibrosis) ‘ ee normal bone marrow ibro-osteosclerosis Unmet medical need 3,000 cases diagnosed par year in the US = "13,000 people in the US living with MF Median survival:~1-3 years for i
Slide 7: Phase 2 Trial in Myelofibrosis (IMbark)
Phase 2 Trial in Myelofibrosis (IMbark™) An open label, single-blind study being conducted by Janssen Biotech, Inc. + Multi-center across North America, Europe and Asia + Objectives: Define proper dosing and confirm efficacy using current validated regulatory endpoints + Opened for enrollment in Jul
Slide 8: IMbark Rationale for Study Design
IMbark™ Rationale for Study Design Targets significant unmet medical need population Pater + No approved alternative therapies beyond Jakafi + Median survival reported to be approximately 6 months + 3-year discontinuation rate for Jakafi ~86% — Major reasons: loss of therapeutic effect and lack of r
Slide 9: Myelodysplastic Syndromes (MDS)
splastic Syndromes (MDS) haracteristics + Most common myeloid malignancy Diverse group of clonal hematologic malignancies —~12,000 cases diagnosed per year in the US with disordered and ineffective production of the "60,000 people in the US living with MDS myeloid lineage in the bone marrow characte
Slide 10: Myelodysplastic Syndromes: Anemia Remains an Unmet Need
splastic Syndromes (MDS) emia Remains an Unmet Need Treatments for lower risk MDS patients + Erythropoiesis stimulating agent (ESA): Patients may experience a transient (median duration ~2 years) improvement in anemia Patients who do not respond or who relapse within 6 months are predicted to have p
Slide 11: Dosing of Imetelstat in Mayo Clinic Pilot Cohort: Clinical Rationale in MDS
ig of Imetelstat in Mayo Clinic Pilot Coh s Clinical Rationale in MDS Data presented at the ASH Annual Meeting in December 2015 + 9 patients with MDS-RARS (refractory anemia with ring sideroblasts) = IPSS risk classification: intermediate-1 (n=7); intermediate-2 (n=2) ~All patients were anemic (hemo
Slide 12: Phase 2/3 Trial in MDS (IMerge)
Trial in MDS ) A two part study being conducted by Janssen Biotech, Inc. IMe * Multicenter across North & South America, Europe and Asia + Objectives: Part 1 (Ph 2) to evaluate safety and efficacy of imetelstat to advance to Part 2 based on positive assessment of benefit-risk profile; Part 2 (Ph 3)
Slide 13: IMerge Rationale for Study Design
for Study Design . Targets significant unmet medical need population Patient + Chronic anemia remains clinical problem in lower risk MDS Population * No approved alternative therapies upon resistance or relapse to ESAs* Primary endpoint reflects current validated regulatory pathway + Transfusion ind
Slide 14: Milestones for IMbark and IMerge in 2016 and 2017
tones for IMbark™ and IMer, is for 2016 and 2017 1H 2016 I 2H 2016 | 1H 2017 2H 2017 T © First patient dosed © Internal data review © IMerge™ Part 2 © Primary analysis, for IMerge™ Part 1 for IMbark" ‘open for enrollment for IMbark™ {conducted after 20 (conducted after patients from each all patient
Slide 15: Slide 15